Navigation Links
Circassia's Allergy Therapy Begins Phase II Clinical Trial in Asthma Patients
Date:4/21/2009

t Circassia

Circassia is a specialty biopharmaceutical company focused on the field of allergy. The company's range of allergy therapeutics utilizes its proprietary T-cell epitope desensitization technology, ToleroMune. Circassia's anti-allergy products offer potential major clinical benefits compared with existing therapies, and consequently have significant market opportunities. Over 150 million people suffer from allergic rhinitis in the US and Europe, and the market for current treatments is approximately $12 billion per year. The prevalence of cat allergies is also high, with 1-in-6 Americans and nearly 10% of Europeans suffering from the condition.

ToleroMune technology has additional potential regulatory and supply benefits for Circassia. Its state-of-the-art manufacturing fits with changes in the European regulatory environment, where authorities are increasingly treating allergen immunotherapies as pharmaceutical products, and eliminating the batch-to-batch potency variability that is an intrinsic feature of many currrent treatments.

Circassia has a highly experienced management team with a proven track record in product development and commercialization. Having successfully completed two fundraising rounds the company is backed by a syndicate of world-class venture capital and institutional investors, including Imperial Innovations, Lansdowne Partners, Goldman Sachs and Invesco Perpetual.

    For more information please visithttp://www.circassia.co.uk.

    Contacts

    Steve Harris                 Rob Budge
    CEO                          RJB Communications
    Circassia Tel:                       +44-(0)1865-760969
    Tel: +44-(0)1865-784574      Mobile: +44-(0)7710-741241


'/>"/>
SOURCE Circassia Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment
2. Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology
3. Circassia Achieves Successful Phase II Clinical Results With Toleromune(R) Anti-Allergy Technology
4. American Lung Association Study Finds No Evidence of Depression or Suicide Linked to Asthma and Allergy Drug Montelukast
5. Study Says Allergy Shots Help Children, Reduce Health Care Costs
6. SAIC Awarded Malaria Vaccine Production Support Contract Extension by the National Institute of Allergy and Infectious Diseases
7. Muscadine Grape Skin Dietary Supplement Protects against Cancer Therapy Radiation Side Effects
8. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
9. Pivotal Clinical Data Published for the Only Laser Phototherapy Device Cleared by the FDA for Hair Growth
10. MitraClip(R) Therapy Data Shows Important Clinical Benefit in High Risk Patients With Functional Mitral Regurgitation at 12-Month Follow Up
11. Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... ALBANY, New York , July 11, 2014 /PRNewswire/ ... published by Transparency Market Research "Endoscopy Devices Market (Endoscopes, ... Analysis, Size, Share, Growth, Trends and Forecast, 2013-2019" the ... billion in 2012 and is expected to grow at ... reach an estimated value of USD 36.9 billion in ...
(Date:7/11/2014)... , July 11, 2014 ... to Safety & Health Expo 2014 were ... move to London , ... attending exhibition.          ... http://photos.prnewswire.com/prnh/20140711/696892-a )      (Photo: ...
(Date:7/10/2014)... , 11. Juli 2014  Dilon ... für die molekulare Bildgebung, einschließlich molekularer ... die CE-Zulassung für sein Navigator ® ... Dilon das Produkt jetzt europaweit vertreiben. ... Großteil der europäischen Länder ausgedehnt und ...
Breaking Medicine Technology:Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2
... BellaNovus Development Company LLC, a medical design ... the Ouchless™ Needle Collection. The devices provide doctors ... creams and ice currently used to minimize localized ... and dermal fillers. Offered in three models, Ouchless™ ...
... CIVCO Medical Solutions is showcasing its RFSuite RFID tracking ... also hosting an RFSuite Symposium Monday, August 1st, from ... the Fairmont Waterfront, Vancouver. The event will include lunch, ... Click here to view the invitation and register . ...
Cached Medicine Technology:New Ouchless™ Needle Collection Revolutionizes Wrinkle Treatments With State-of-the-Art Pain Reducing Technology 2CIVCO Showcases RFSuite RFID Tracking and Verification System at AAPM 2011 Booth #817 2CIVCO Showcases RFSuite RFID Tracking and Verification System at AAPM 2011 Booth #817 3
(Date:7/14/2014)... York, NY (PRWEB) July 14, 2014 ... app on iTunes, called Love Digits. The App brings ... and couples alike to quantify their compatibility using a ... and places, two people can instantaneously test their compatibility ... Chinese astrology measures. , The app’s five-star rating system ...
(Date:7/14/2014)... New research and analysis from the ... Earth examines toxic ingredients in tampons, a product ... specific chemicals that may be found in the product’s ... may put women’s health at risk. , According ... Scranton , the potential impact of toxic chemical exposure ...
(Date:7/13/2014)... Recently, MagicQuinceaneraDresses.com, a well-known special occasion dress manufacturer and ... Dama dresses . Furthermore, the company’s sales manager has ... sale. They are available at greatly discounted prices, up ... to unveil the cheap, fashionable Dama gowns. “By launching ... for our fans. It will last until July 26. ...
(Date:7/13/2014)... Denver, CO (PRWEB) July 13, 2014 ... in conjunction with the 2014 Guinness International Champions Cup. ... on American soil each year because of the talent of ... Manchester United and AS Roma will compete in the 2014 ... off on July 24 with a game between Olympiacos and ...
(Date:7/13/2014)... Failure to get the best treatment and variations in ... why survival for blood cancer patients still varies widely ... study of survival in European adults to date, published ... news is that 5-year survival for most cancers of ... most likely reflecting the approval of new targeted drugs ...
Breaking Medicine News(10 mins):Health News:Love Digits, Numerical Approach to Modern Love, Now Available on iTunes 2Health News:Love Digits, Numerical Approach to Modern Love, Now Available on iTunes 3Health News:New Patent Analysis Shows Toxic Risk From Tampons 2Health News:New Patent Analysis Shows Toxic Risk From Tampons 3Health News:New Patent Analysis Shows Toxic Risk From Tampons 4Health News:New Patent Analysis Shows Toxic Risk From Tampons 5Health News:Fashionable Dama Dresses Unveiled By Well-known Supplier MagicQuinceaneraDresses.com 2Health News:Manchester United vs. AS Roma Tickets in Denver, CO at Sports Authority Field at Mile High: Ticket Down Slashes Ticket Prices on International Champions Cup in Denver 2Health News:Manchester United vs. AS Roma Tickets in Denver, CO at Sports Authority Field at Mile High: Ticket Down Slashes Ticket Prices on International Champions Cup in Denver 3Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 2Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 3
... , SATURDAY, June 4 (HealthDay News) -- Breast cancer ... diagnosis have a lower chance of surviving, a new study ... cancer and obesity only in estrogen receptor-positive forms of the ... breast cancer. "This relationship between dying and being obese ...
... a healthy body weight before and after diagnosis of breast ... a new study finds. The results will be presented Saturday ... The study, conducted in nearly 4,000 breast cancer survivors, found ... cancer. In particular, overweight or obese women with a history ...
... radiation treatment improves disease free survival lessening the chance ... who have had breast conserving surgery (lumpectomy), interim results ... presented Monday, June 6 at the annual meeting of ... results are potentially practice-changing," said Dr. Timothy J. Whelan, ...
... Reporter , FRIDAY, June 3 (HealthDay News) -- Early ... the cancer,s return drop by 32 percent when the ... for three years after surgery, Austrian researchers report. ... to develop osteoporosis, so they are usually given a ...
... June 3 (HealthDay News) -- Providing children with more toys ... researchers say. The new study also found that having ... play among children, particularly girls. In the ... of Buffalo in New York, researchers offered three different quantities ...
... M.D., Ph.D. , the associate director of the Acute and ... a Career Development Award from the Conquer Cancer Foundation of the ... Foundation) at the annual ASCO meeting this weekend in ... at the Mayo Clinic News Blog . Dr. ...
Cached Medicine News:Health News:Excess Pounds May Lower Odds of Surviving Breast Cancer 2Health News:Obesity raises breast cancer survivors' risk of dying of the cancer 2Health News:Breast cancer surgery patients benefit from adding radiation therapy 2Health News:Bone Drug Reduces Odds for Breast Cancer's Return: Study 2Health News:Bone Drug Reduces Odds for Breast Cancer's Return: Study 3Health News:Having More Toys May Boost Exercise Levels in Kids 2Health News:Mayo Clinic: Raoul Tibes, M.D., Ph.D., to receive Career Development Award 2
... Easy Breeze Air Gel Dryer : Dry up ... 24 gels 8 10 cm without a ... rapid drying, or no heat for controlled drying ... transparent, dried gels. Add and remove gels at ...
Each GelAir™ system drying frame includes two main components, a plastic drying outer frame and a metal square inner frame, as well as 8 clamps per frame. Supplied as a set of two frames....
... Breeze Air Gel Dryer : Dry up to ... gels 8 10 cm without a vacuum ... drying, or no heat for controlled drying of ... dried gels. Add and remove gels at any ...
... SGD5040 Slab Gel Dryer incorporates sturdy metal housing and ... The large surface area makes it perfect for drying ... Slim Profile 40cm x 50cm (W x D) ... Rates allows you to optimize your heating ...
Medicine Products: